259 related articles for article (PubMed ID: 36742345)
1. KIF11 As a Potential Pan-Cancer Immunological Biomarker Encompassing the Disease Staging, Prognoses, Tumor Microenvironment, and Therapeutic Responses.
Guo X; Zhou L; Wu Y; Li J
Oxid Med Cell Longev; 2022; 2022():2764940. PubMed ID: 36742345
[TBL] [Abstract][Full Text] [Related]
2. MXD3 as an onco-immunological biomarker encompassing the tumor microenvironment, disease staging, prognoses, and therapeutic responses in multiple cancer types.
Wu SY; Lin KC; Lawal B; Wu ATH; Wu CZ
Comput Struct Biotechnol J; 2021; 19():4970-4983. PubMed ID: 34584637
[TBL] [Abstract][Full Text] [Related]
3. Mitotic Functions and Characters of KIF11 in Cancers.
Gao W; Lu J; Yang Z; Li E; Cao Y; Xie L
Biomolecules; 2024 Mar; 14(4):. PubMed ID: 38672404
[TBL] [Abstract][Full Text] [Related]
4. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact and Functional Annotations of KIF11 and KIF14 Expression in Patients with Colorectal Cancer.
Neska-Długosz I; Buchholz K; Durślewicz J; Gagat M; Grzanka D; Tojek K; Klimaszewska-Wiśniewska A
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575892
[TBL] [Abstract][Full Text] [Related]
6. A systematic pan-cancer analysis identifies LDHA as a novel predictor for immunological, prognostic, and immunotherapy resistance.
Zhang Q; Luo Y; Qian B; Cao X; Xu C; Guo K; Wan R; Jiang Y; Wang T; Mei Z; Liu J; Lv C
Aging (Albany NY); 2024 May; 16(9):8000-8018. PubMed ID: 38709280
[TBL] [Abstract][Full Text] [Related]
7. YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy.
Hu J; Qiu D; Yu A; Hu J; Deng H; Li H; Yi Z; Chen J; Zu X
Front Oncol; 2021; 11():607224. PubMed ID: 34026603
[TBL] [Abstract][Full Text] [Related]
8. KIF11 as a potential cancer prognostic marker promotes tumorigenesis in children with Wilms tumor.
Luo Y; Liu W; Zhu Y; Tian Y; Wu K; Ji L; Ding L; Zhang W; Gao T; Liu X; Zhao J
Pediatr Hematol Oncol; 2022 Mar; 39(2):145-157. PubMed ID: 34378481
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of KIF11 in TP53 Mutant Glioma Promotes Tumor Stemness and Drug Resistance.
Liu B; Zhang G; Cui S; Du G
Cell Mol Neurobiol; 2022 Jul; 42(5):1477-1485. PubMed ID: 33491154
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
Front Immunol; 2021; 12():781087. PubMed ID: 35069553
[TBL] [Abstract][Full Text] [Related]
11. Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness.
Piao XM; Byun YJ; Jeong P; Ha YS; Yoo ES; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2017 Aug; 15(4):450-454. PubMed ID: 27842896
[TBL] [Abstract][Full Text] [Related]
12. Pan-cancer analysis shows that IBSP is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including osteosarcoma.
Pan B; Cheng X; Tan W; Liu R; Wu X; He J; Fan Q; Zhang Y; Cheng J; Deng Y
Front Immunol; 2023; 14():1188256. PubMed ID: 37457709
[TBL] [Abstract][Full Text] [Related]
13. High KIF11 expression is associated with poor outcome of NSCLC.
Liu J; Tian Y; Yi L; Gao Z; Lou M; Yuan K
Tumori; 2022 Feb; 108(1):40-46. PubMed ID: 33554761
[TBL] [Abstract][Full Text] [Related]
14. ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis.
Lin Y; Zhang Y; Tuo Z; Gao L; Ding D; Bi L; Yu D; Lv Z; Wang J; Chen X
BMC Cancer; 2023 Mar; 23(1):285. PubMed ID: 36978046
[TBL] [Abstract][Full Text] [Related]
15. PRAME Is a Potential Carcinogenic Biomarker that Correlates with Patient Prognosis and Tumor Immunity Based on Pan-Cancer Analysis.
Zhao Q; Zhang Z; Wu Y
Ann Clin Lab Sci; 2022 Mar; 52(2):185-195. PubMed ID: 35414497
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker.
Meng W; Jiang Z; Zhang X; Cai B; Ma L; Guan Y
Comput Math Methods Med; 2022; 2022():3119721. PubMed ID: 36466552
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of the expression profile and clinical implications of regulator of chromosome condensation 2 in pan-cancers.
Li X; Kang K; Peng Y; Shen L; Shen L; Zhou Y
Aging (Albany NY); 2022 Nov; 14(22):9221-9242. PubMed ID: 36441563
[TBL] [Abstract][Full Text] [Related]
18. Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker.
Qiu Y; Wang H; Liao P; Xu B; Hu R; Yang Y; Li Y
BMC Genom Data; 2022 Jan; 23(1):7. PubMed ID: 35033016
[TBL] [Abstract][Full Text] [Related]
19. CCDC58 is a potential biomarker for diagnosis, prognosis, immunity, and genomic heterogeneity in pan-cancer.
Yang K; Ma Y; Chen W; Liu L; Yang Z; He C; Zheng N; Liu X; Cheng X; Song J; Chen Y; Qiao H; Zhang R
Sci Rep; 2024 Apr; 14(1):8575. PubMed ID: 38609450
[TBL] [Abstract][Full Text] [Related]
20. Investigating the role of Kinesin family in lung adenocarcinoma via integrated bioinformatics approach.
Tabassum G; Singh P; Gurung R; Hakami MA; Alkhorayef N; Alsaiari AA; Alqahtani LS; Hasan MR; Rashid S; Kumar A; Dev K; Dohare R
Sci Rep; 2023 Jun; 13(1):9859. PubMed ID: 37330525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
